Use of Proton-Pump Inhibitors Is Associated with Excess Risk for Osteoporosis-Related Fractures

Acid secreted by the stomach facilitates absorption of calcium by the small intestine. Proton-pump inhibitors (PPIs) inhibit gastric acid production and, therefore, can reduce calcium absorption and bone density. Using a population-based data registry, Canadian investigators assessed previous use of PPIs among 15,792 patients (age, ≥50) with osteoporosis-related fractures (vertebral, wrist, and hip fractures) and 47,289 patients (matched for age, sex, ethnicity, and comorbid illness) without fractures. The study period was from 1996 to 2004.

After adjustment for potential confounders, continuous PPI use for ≤6 years was not associated with excess risk for osteoporosis-related fracture. Continuous use of PPIs for ≥7 years, however, was associ…